Nissay Asset Management Corp Japan ADV Cuts Holdings in Cencora, Inc. (NYSE:COR)

Nissay Asset Management Corp Japan ADV lowered its stake in Cencora, Inc. (NYSE:COR) by 1.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 21,248 shares of the company’s stock after selling 338 shares during the period. Nissay Asset Management Corp Japan ADV’s holdings in Cencora were worth $4,822,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also made changes to their positions in the company. Whittier Trust Co. increased its holdings in Cencora by 0.6% in the fourth quarter. Whittier Trust Co. now owns 7,856 shares of the company’s stock valued at $1,765,000 after buying an additional 44 shares during the last quarter. Shepherd Financial Partners LLC boosted its position in shares of Cencora by 0.9% during the 4th quarter. Shepherd Financial Partners LLC now owns 5,441 shares of the company’s stock worth $1,223,000 after acquiring an additional 46 shares in the last quarter. WASHINGTON TRUST Co boosted its position in shares of Cencora by 37.7% during the 4th quarter. WASHINGTON TRUST Co now owns 168 shares of the company’s stock worth $38,000 after acquiring an additional 46 shares in the last quarter. JFS Wealth Advisors LLC increased its holdings in shares of Cencora by 63.0% in the 4th quarter. JFS Wealth Advisors LLC now owns 119 shares of the company’s stock valued at $27,000 after acquiring an additional 46 shares during the last quarter. Finally, Cullen Frost Bankers Inc. raised its position in shares of Cencora by 1.1% during the 4th quarter. Cullen Frost Bankers Inc. now owns 4,463 shares of the company’s stock worth $1,003,000 after acquiring an additional 47 shares in the last quarter. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Cencora Price Performance

Shares of COR opened at $285.51 on Friday. The company has a debt-to-equity ratio of 16.40, a quick ratio of 0.54 and a current ratio of 0.92. Cencora, Inc. has a fifty-two week low of $214.77 and a fifty-two week high of $309.35. The firm has a 50-day simple moving average of $278.51 and a 200-day simple moving average of $254.58. The company has a market capitalization of $55.37 billion, a price-to-earnings ratio of 40.61, a price-to-earnings-growth ratio of 1.31 and a beta of 0.60.

Cencora (NYSE:COR) last posted its quarterly earnings data on Wednesday, May 7th. The company reported $4.42 earnings per share for the quarter, topping analysts’ consensus estimates of $4.07 by $0.35. The company had revenue of $75.50 billion during the quarter, compared to analysts’ expectations of $75.41 billion. Cencora had a return on equity of 328.62% and a net margin of 0.46%. The firm’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same period last year, the firm earned $3.80 EPS. On average, equities research analysts anticipate that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, June 2nd. Investors of record on Friday, May 16th will be given a $0.55 dividend. The ex-dividend date is Friday, May 16th. This represents a $2.20 dividend on an annualized basis and a yield of 0.77%. Cencora’s dividend payout ratio (DPR) is 25.52%.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the company. Morgan Stanley set a $288.00 price target on Cencora in a report on Tuesday, April 15th. Wells Fargo & Company upped their target price on shares of Cencora from $251.00 to $274.00 and gave the company an “equal weight” rating in a report on Friday, March 14th. Robert W. Baird increased their target price on shares of Cencora from $314.00 to $350.00 and gave the company an “outperform” rating in a research report on Thursday, May 8th. JPMorgan Chase & Co. boosted their price target on shares of Cencora from $289.00 to $301.00 and gave the company an “overweight” rating in a research report on Friday, January 24th. Finally, Bank of America raised their price objective on Cencora from $270.00 to $285.00 and gave the stock a “neutral” rating in a report on Friday, April 11th. Two analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to data from MarketBeat, Cencora has a consensus rating of “Moderate Buy” and a consensus target price of $301.18.

Insider Buying and Selling at Cencora

In related news, EVP Silvana Battaglia sold 5,000 shares of the firm’s stock in a transaction dated Friday, February 21st. The shares were sold at an average price of $242.24, for a total value of $1,211,200.00. Following the completion of the sale, the executive vice president now owns 15,374 shares in the company, valued at $3,724,197.76. This trade represents a 24.54% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CAO Lazarus Krikorian sold 2,000 shares of Cencora stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $260.06, for a total value of $520,120.00. Following the completion of the sale, the chief accounting officer now directly owns 20,154 shares in the company, valued at $5,241,249.24. This represents a 9.03% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 50,223 shares of company stock valued at $13,580,967. 10.80% of the stock is owned by company insiders.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.